Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Mersana Therapeutics ( (MRSN) ) is now available.
On June 2, 2025, Mersana Therapeutics announced positive interim data from its Phase 1 clinical trial of Emi-Le, a B7-H4-directed Dolasynthen ADC, at the ASCO Annual Meeting. The trial showed promising objective response rates in various cancer types, including triple-negative breast cancer and adenoid cystic carcinoma, with a favorable safety profile. These results highlight Emi-Le’s potential to address high unmet needs in the ADC field.
The most recent analyst rating on (MRSN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Mersana Therapeutics stock, see the MRSN Stock Forecast page.
Spark’s Take on MRSN Stock
According to Spark, TipRanks’ AI Analyst, MRSN is a Underperform.
Mersana Therapeutics is under significant financial strain, characterized by negative equity and substantial losses. Despite some technical neutrality, the stock shows weak valuation metrics. The company’s restructuring may offer future benefits, but current financial health and technical indicators suggest caution.
To see Spark’s full report on MRSN stock, click here.
More about Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs. The company has developed proprietary platforms, Dolasynthen and Immunosynthen, which have generated a pipeline of product candidates aimed at treating various cancers.
Average Trading Volume: 2,943,166
Technical Sentiment Signal: Sell
Current Market Cap: $42.84M
For an in-depth examination of MRSN stock, go to TipRanks’ Stock Analysis page.